Podcasts about pardoll

  • 6PODCASTS
  • 11EPISODES
  • 21mAVG DURATION
  • ?INFREQUENT EPISODES
  • Sep 12, 2021LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about pardoll

Latest podcast episodes about pardoll

MIB Agents OsteoBites
Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient

MIB Agents OsteoBites

Play Episode Listen Later Sep 12, 2021 88:21


Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient Dr. Huang is back on OSTEOBites to give us an update on his research funded by OutSmarting Osteosarcoma 2019. Don't miss this exciting new episode, plus who doesn't love Dr. Huang? ABOUT Alex Huang, MD, PhD: Dr. Huang received a B.S. in chemistry and an M.S. in biochemistry and molecular biology from the University of Chicago. He then entered the medical scientist training program at the Johns Hopkins University School of Medicine, where he completed his Ph.D. thesis in the laboratory of Drew M. Pardoll, M.D., Ph.D. Dr. Huang's Ph.D. thesis included studying the process of in vivo tumor-antigen cross-presentation by bone marrow derived professional antigen presenting cells and identified the dominant MHC class-I restricted tumor rejection antigen, AH-1, in a murine colon tumor model. Hosted by: Executive Director of MIB Agents - Ann Graham OsteoWarrior and MIB Junior Board Member - Shannon McCormack MIB Super Volunteer Amy Woodchecke PA-C. LINKS: VIDEO of this Podcast: https://youtu.be/eRTS2S8li-I BOWS: https://www.mibagents.org/bows ANGEL WALL: In memory of OsteoAngels: https://www.youtube.com/watch?v=M6Cbe-1m72s&t=558s Note: Note: Dr. Huang's cousin, Wenwei is at 9:18 HUANG LAB: http://www.huanglab.com Dr. Huang's Email: alex.y.huang@case.edu Clinical Trial Search: www.mibagents.org/physicians-researchers/clinical-trials … What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts Bereaved Parent Support ✨ Ambassador Agents - Peer Support EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: ✨ Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

GRACEcast
Questions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. West

GRACEcast

Play Episode Listen Later Dec 31, 2014 17:00


Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.

GRACEcast Treatments and Support Video
Questions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. West

GRACEcast Treatments and Support Video

Play Episode Listen Later Dec 31, 2014 17:00


Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.

GRACEcast ALL Subjects audio and video
Questions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. West

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 31, 2014 17:00


Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.

GRACEcast
What is Immunotherapy and its Mechanisms of Action? Part 2

GRACEcast

Play Episode Listen Later Dec 15, 2014 14:26


Immunotherapy Forum Video #2: In Part 2 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.

GRACEcast Social Work and Coping Video
What is Immunotherapy and its Mechanisms of Action? Part 2

GRACEcast Social Work and Coping Video

Play Episode Listen Later Dec 15, 2014 14:26


Immunotherapy Forum Video #2: In Part 2 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.

GRACEcast ALL Subjects audio and video
What is Immunotherapy and its Mechanisms of Action? Part 2

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 15, 2014 14:26


Immunotherapy Forum Video #2: In Part 2 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.

GRACEcast
What is Immunotherapy and its Mechanisms of Action? Part 1

GRACEcast

Play Episode Listen Later Dec 10, 2014 15:59


Immunotherapy Forum Video #1: In Part 1 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.

GRACEcast Treatments and Support Video
What is Immunotherapy and its Mechanisms of Action? Part 1

GRACEcast Treatments and Support Video

Play Episode Listen Later Dec 10, 2014 15:59


Immunotherapy Forum Video #1: In Part 1 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.

GRACEcast ALL Subjects audio and video
What is Immunotherapy and its Mechanisms of Action? Part 1

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 10, 2014 15:59


Immunotherapy Forum Video #1: In Part 1 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.

WIN Symposium 2013
Establishing immunotherapy as a standard in cancer treatment: Dr Drew Pardoll

WIN Symposium 2013

Play Episode Listen Later Jul 22, 2013 9:32


Prof Drew Pardoll talks to ecancer at the 2013 WIN Symposium in Paris about the recent developments in treating cancer with immunotherapy. Immunotherapy for cancer aims to empower the immune system's antibodies and T-Cells to attack tumours. This occurs through the blockade of regulatory pathways, immune checkpoints, and the reactivation of T-Cells. The most recent breakthrough in this field has been the results in blocking PD-1 with ipilimumab.